Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$2.10 - $35.15
Next Earnings Date
Apr 29 2025
Next Earnings Date
Apr 29 2025
Latest price
Market Cap | $24.51B |
EV | $24.11B |
Shares Outstanding | 796.87M |
Beta | -0.46 |
Analyst Rating | BUY |
Analyst Target Price | $35.48 |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | - |
EPS | 31.60% |
Operating Cash Flow | -24.70% |
Free Cash Flow | -54.60% |
Revenue | - |
EPS | -31.00% |
Operating Cash Flow | -24.40% |
Free Cash Flow | -34.20% |
Gross Margin 2025E | - |
Net Profit Margin 2025E | - |
ROE 2025E | -75.69% |
ROCE 2024 | -94.90% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Summit Therapeutics Inc.
SMMT
Sector
Healthcare
Industry
Biotechnology
CEO
Data Unavailable
Employees
159
Website
www.summittxinc.comIPO Date
2015-03-05
Headquarters
601 Brickell Key Drive, Suite 1000, Miami, Florida, 33131, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved